Show simple item record

dc.contributor.authorWeber, Minéia
dc.contributor.authorMera, Paula
dc.contributor.authorCasas, Josefina
dc.contributor.authorSalvador, Javier
dc.contributor.authorRodríguez, Amaia
dc.contributor.authorAlonso, Sergio
dc.contributor.authorSebastián, David
dc.contributor.authorSoler-Vázquez, M. Carmen
dc.contributor.authorMontironi, Carla
dc.contributor.authorRecalde, Sandra
dc.contributor.authorFucho, Raquel
dc.contributor.authorCalderón-Domínguez, María
dc.contributor.authorMir, Joan Francesc
dc.contributor.authorBartrons, Ramon
dc.contributor.authorEscola-Gil, Joan Carles
dc.contributor.authorSánchez-Infantes, David
dc.contributor.authorZorzano, Antonio
dc.contributor.authorLlorente-Cortes, Vicenta
dc.contributor.authorCasals i Farré, Núria
dc.contributor.authorValentí, Víctor
dc.contributor.authorFrühbeck, Gema
dc.contributor.authorHerrero Rodríguez, Laura
dc.contributor.authorSerra, Dolors
dc.date.accessioned2020-10-29T18:24:39Z
dc.date.available2020-10-29T18:24:39Z
dc.date.issued2020
dc.identifier.citationWeber, Minéia; Mera, Paula; Casas, Josefina [et al.]. Liver CPT1A gene therapy reduces diet‐induced hepatic steatosis in mice and highlights potential lipid biomarkers for human NAFLD. Federation of American Societies for Experimental Biology, 2020, 34(9), p. 11816–11837. Disponible en: <https://faseb.onlinelibrary.wiley.com/doi/full/10.1096/fj.202000678R>. Fecha de acceso: 29 oct. 2020. DOI: 10.1096/fj.202000678Rca
dc.identifier.issn0892-6638ca
dc.identifier.urihttp://hdl.handle.net/20.500.12328/1703
dc.description.abstractThe prevalence of nonalcoholic fatty liver disease (NAFLD) has increased drastically due to the global obesity pandemic but at present there are no approved therapies. Here, we aimed to revert high‐fat diet (HFD)‐induced obesity and NAFLD in mice by enhancing liver fatty acid oxidation (FAO). Moreover, we searched for potential new lipid biomarkers for monitoring liver steatosis in humans. We used adeno‐associated virus (AAV) to deliver a permanently active mutant form of human carnitine palmitoyltransferase 1A (hCPT1AM), the key enzyme in FAO, in the liver of a mouse model of HFD‐induced obesity and NAFLD. Expression of hCPT1AM enhanced hepatic FAO and autophagy, reduced liver steatosis, and improved glucose homeostasis. Lipidomic analysis in mice and humans before and after therapeutic interventions, such as hepatic AAV9‐hCPT1AM administration and RYGB surgery, respectively, led to the identification of specific triacylglyceride (TAG) specie (C50:1) as a potential biomarker to monitor NAFFLD disease. To sum up, here we show for the first time that liver hCPT1AM gene therapy in a mouse model of established obesity, diabetes, and NAFLD can reduce HFD‐induced derangements. Moreover, our study highlights TAG (C50:1) as a potential noninvasive biomarker that might be useful to monitor NAFLD in mice and humans.ca
dc.format.extent22ca
dc.language.isoengca
dc.publisherJohn Wiley & Sons, Inc.ca
dc.relation.ispartofFederation of American Societies for Experimental Biologyca
dc.relation.ispartofseries34;9
dc.rights© 2020 The Authors. The FASEB Journal published by Wiley Periodicals LLC on behalf of Federation of American Societies for Experimental Biology. This is an open access article under the terms of the Creative Commons Attribution NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.ca
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/
dc.subject.otherOxidacióca
dc.subject.otherÀcids grassosca
dc.subject.otherTeràpia genèticaca
dc.subject.otherEsteatosi hepàticaca
dc.subject.otherMarcadors bioquímicsca
dc.subject.otherObesitatca
dc.subject.otherFetgeca
dc.subject.otherOxidaciónca
dc.subject.otherÁcidos grasosca
dc.subject.otherTerapia genéticaca
dc.subject.otherEsteatosis hepáticaca
dc.subject.otherMarcadores bioquímicosca
dc.subject.otherObesidadca
dc.subject.otherHígadoca
dc.subject.otherOxidationca
dc.subject.otherFatty acidsca
dc.subject.otherGenetic therapyca
dc.subject.otherHepatic steatosisca
dc.subject.otherBiochemical markersca
dc.subject.otherObesityca
dc.subject.otherLiverca
dc.titleLiver CPT1A gene therapy reduces diet‐induced hepatic steatosis in mice and highlights potential lipid biomarkers for human NAFLDca
dc.typeinfo:eu-repo/semantics/articleca
dc.description.versioninfo:eu-repo/semantics/publishedVersionca
dc.rights.accessLevelinfo:eu-repo/semantics/openAccess
dc.embargo.termscapca
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/1PE/SAF2014-52223-C2-1-Rca
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/2PE/SAF2017-83813-C3-1-Rca
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/2PE/SAF2017-82813-C3-3Rca
dc.subject.udc61ca
dc.subject.udc616.4ca
dc.identifier.doihttps://dx.doi.org/10.1096/fj.202000678Rca


Files in this item

 

This item appears in the following Collection(s)

Show simple item record

© 2020 The Authors. The FASEB Journal published by Wiley Periodicals LLC on behalf of Federation of American Societies for Experimental Biology. This is an open access article under the terms of the Creative Commons Attribution NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc/4.0/